For example, therapeutic approaches have been aimed at targeting EGFR amplifications, which is the most common genetic alteration in GBM, occurring in approximately 50% of the cases, as well as its variant EGFRvIII, a mutation found in a subset of GBM cases [29]. The gene discussed is EGFR; the disease is glioblastoma.